polycythemia vera

Novartis: EU approval for Jakavi® for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea

Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea…

9 years ago

Novartis: CHMP of the European Medicines Agency adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and…

9 years ago